Myriad Appoints Jan Schluchter as Chief Commercial Officer for Europe
October 01 2015 - 7:05AM
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in the personalized
medicine industry with innovative, high-quality molecular
diagnostics, today announced that Jan Schlüchter, Ph.D., has joined
the Company as chief commercial officer (CCO) of Myriad Genetics
GmbH, effective Oct. 15, 2015. He will report to Gary King,
executive vice president, International Operations.
"Our international business represents a significant long-term
growth opportunity for Myriad and the European region is our
biggest near-term opportunity," said King. "We are delighted to
welcome Jan Schlüchter as our new chief commercial officer. His
experience in leading and transforming healthcare businesses will
help us accelerate growth internationally."
Myriad Genetics GmbH is the Zurich-based international
subsidiary of Myriad Genetics, Inc. and oversees the international
operations outside the United States. As the CCO, Dr. Schlüchter
will lead country operations in Europe to drive new growth
opportunities, offering superior molecular diagnostic solutions for
patients, physicians and payors. He will focus on commercializing
the Company's portfolio of hereditary cancer tests, companion
diagnostics and high-value test kits.
"I am excited to be joining an organization that is passionate
about helping patients make the right healthcare decisions with its
pioneering molecular diagnostics," said Dr. Schlüchter. "It is an
exciting time at Myriad as the company advances its pipeline and
expands its commercial activities internationally. Our goal is to
make new leading molecular diagnostic solutions accessible to all
patients globally, and I am looking forward to working with our key
stakeholders."
Dr. Schlüchter has held several senior positions at Novartis
over the past 12 years. Most recently he served as Global Head of
Key Account Management at Novartis' headquarters in Basel,
Switzerland. Previously, he held General Management roles in Greece
and Germany. Before Novartis, Dr. Schlüchter was a Consultant at
McKinsey and has founded two companies. He received his master's
degree in management from the University of Nuremberg, Germany and
his doctor of philosophy degree in marketing from the University of
Dortmund, Germany.
About Myriad Genetics GmbH
Myriad Genetics GmbH is the international subsidiary of Myriad
Genetics, Inc. It has established international headquarters in
Zurich, Switzerland, a full service laboratory in Munich, Germany
and offices in Munich, Germany; Paris, France; Madrid, Spain;
Milan, Italy; London, UK; and Zurich, Switzerland. Additionally,
Myriad Genetics GmbH has a network of distributors worldwide. For
more information visit: www.myriadgenetics.eu.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic company
dedicated to making a difference in patients' lives through the
discovery and commercialization of transformative tests to assess a
person's risk of developing disease, guide treatment decisions and
assess risk of disease progression and recurrence. Myriad is
focused on strategic directives to grow existing markets, diversify
through the introduction of new products, including companion
diagnostics, as well as to expand internationally. For more
information on how Myriad is making a difference, please visit the
Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris
AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan Lung
Cancer, BRACAnalysis CDx, HRD, Vectra and Prolaris are trademarks
or registered trademarks of Myriad Genetics, Inc. in the United
States and foreign countries. MYGN-F, MYGN-G
Safe Harbor Statement
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements related to the hiring of Jan Schlüchter
and the scope of his employment responsibilities; and the Company's
strategic directives under the caption "About Myriad Genetics."
These "forward-looking statements" are based on management's
current expectations of future events and are subject to a number
of risks and uncertainties that could cause actual results to
differ materially and adversely from those set forth in or implied
by forward-looking statements. These risks and uncertainties
include, but are not limited to: the risk that sales and profit
margins of our molecular diagnostic tests and pharmaceutical and
clinical services may decline; risks related to our ability to
transition from our existing product portfolio to our new tests,
including unexpected costs and delays; risks related to decisions
or changes in governmental or private insurers' reimbursement
levels for our tests or our ability to obtain reimbursement for our
new tests at comparable levels to our existing tests; risks related
to increased competition and the development of new competing tests
and services; the risk that we may be unable to develop or achieve
commercial success for additional molecular diagnostic tests and
pharmaceutical and clinical services in a timely manner, or at all;
the risk that we may not successfully develop new markets for our
molecular diagnostic tests and pharmaceutical and clinical
services, including our ability to successfully generate revenue
outside the United States; the risk that licenses to the technology
underlying our molecular diagnostic tests and pharmaceutical and
clinical services and any future tests and services are terminated
or cannot be maintained on satisfactory terms; risks related to
delays or other problems with operating our laboratory testing
facilities and our healthcare clinic; risks related to public
concern over genetic testing in general or our tests in particular;
risks related to regulatory requirements or enforcement in the
United States and foreign countries and changes in the structure of
the healthcare system or healthcare payment systems; risks related
to our ability to obtain new corporate collaborations or licenses
and acquire new technologies or businesses on satisfactory terms,
if at all; risks related to our ability to successfully integrate
and derive benefits from any technologies or businesses that we
license or acquire; risks related to our projections about our
business, results of operations and financial condition; risks
related to the potential market opportunity for our products and
services; the risk that we or our licensors may be unable to
protect or that third parties will infringe the proprietary
technologies underlying our tests; the risk of patent-infringement
claims or challenges to the validity of our patents or other
intellectual property; risks related to changes in intellectual
property laws covering our molecular diagnostic tests and
pharmaceutical and clinical services and patents or enforcement in
the United States and foreign countries, such as the Supreme Court
decision in the lawsuit brought against us by the Association for
Molecular Pathology et al; risks of new, changing and competitive
technologies and regulations in the United States and
internationally; and other factors discussed under the heading
"Risk Factors" contained in Item 1A of our most recent Annual
Report on Form 10-K for the fiscal year ended June 30, 2015, which
has been filed with the Securities and Exchange Commission, as well
as any updates to those risk factors filed from time to time in our
Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All
information in this press release is as of the date of the release,
and Myriad undertakes no duty to update this information unless
required by law.
CONTACT: Media Contact:
Ron Rogers
(801) 584-3065
rrogers@myriad.com
Investor Contact:
Scott Gleason
(801) 584-1143
sgleason@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Sep 2023 to Sep 2024